

THE ADDITION OF A COST ANALYSIS CHANGES THE OUTCOME OF A TENDER

Evaluating tenders with an additional cost analysis is time-consuming but ends up with relevant new recommendations in the majority of the cases

WHAT WAS DONE

- Since 2017, evaluation for therapeutic areas in Denmark has been based on a clinical evaluation, an economic evaluation and a tendering procedure. Previously the call for tenders was based on clinical evidence only.
- The current process is divided in two. Amgros makes the tender evaluations and the economic evaluations.
- The Danish Medicines Council makes the clinical evaluations.
- A re-evaluation of the therapeutic areas processed was made for the period October 2018 until October 2019.
- The cases were multiple sclerosis, rheumatoid arthritis and severe asthma.

HOW IT WAS DONE

- Drug recommendations from cases with multiple sclerosis, reumatoid arthritis and severe asthma were re-evaluated based on clinical evaluation, tender price and, finally, with or without a cost analysis.
- Scan the QR code to see the cost analysis elements.

FIGURE 1 THERAPEUTIC AREAS WHERE THE COST ANALYSIS CHANGES THE DRUG RECOMMENDATION

CHANGES

	MULTIPLE SCLEROSIS	
	With cost analysis	Without cost analysis
1. LINE	Tecfidera PO	Aubagio PO
2. LINE	Aubagio PO	Tecfidera PO
3. LINE	Copemyl 20 mg SC	Copemyl 20 mg SC

	RHEUMATOID ARTHRITIS	
	With cost analysis	Without cost analysis
1. LINE	Imraldi SC	Zessly IV
2. LINE	Zessly IV	Imraldi SC
3. LINE	Xeljanz PO	Xeljanz PO



WHY IT WAS DONE

- To evaluate whether the drug recommendation obtained after adding a cost analysis was different from the recommendation we could have without the inclusion of a cost analysis.
- The purpose of adding a cost analysis is to achieve a recommendation based on the lowest total price, including the tender price and the derived costs for patients and clinicians associated with the treatment.

WHAT WAS ACHIEVED

- The tender evaluation with additional cost analysis is time consuming but ends up with relevant new recommendations in the majority of the cases.
- The recommendation for severe asthma had a similar outcome regardless of the process used. For multiple sclerosis and rheumatoid arthritis, the cost analysis changed the drug recommendations.

FIGURE 2 THERAPEUTIC AREAS WHERE THE COST ANALYSIS DOES NOT ALTER THE DRUG RECOMMENDATION

NO CHANGES

	SEVERE ASTHMA	
	With cost analysis	Without cost analysis
1. LINE	Nucala SC	Nucala SC
2. LINE	Cinqaero IV	Cinqaero IV
3. LINE	Fasenra	Fasenra



WHAT IS NEXT

In order to balance resource consumption from performing cost analyses and the economic impact on the outcome, the plan is to identify therapeutic areas

where it is not meaningful to conduct a cost analysis. In all other areas a cost analysis will be included in the standard procedures.

